Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy

Hong, Beom-Ju; Kim, Jeongwoo; Jeong, Hoibin; Bok, Seoyeon; Kim, Young-Eun; Ahn, G-One

추천

검색

자료유형: 학술저널

저자정보: Hong, Beom-Ju (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Kim, Jeongwoo (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Jeong, Hoibin (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Bok, Seoyeon (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Kim, Young-Eun (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology) Ahn, G-One (Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology)

저널정보: 대한방사선종양학회 Radiation oncology journal : ROJ Radiation oncology journal : ROJ 제34권 제4호

발행연도: 2016.1

수록면: 239 - 249 (11page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Tumor hypoxia, a common feature occurring in nearly all human solid tumors is a major contributing factor for failures of anticancer therapies. Because ionizing radiation depends heavily on the presence of molecular oxygen to produce cytotoxic effect, the negative impact of tumor hypoxia had long been recognized. In this review, we will highlight some of the past attempts to overcome tumor hypoxia including hypoxic radiosensitizers and hypoxia-selective cytotoxin. Although they were (still are) a very clever idea, they lacked clinical efficacy largely because of 'reoxygenation' phenomenon occurring in the conventional low dose hyperfractionation radiotherapy prevented proper activation of these compounds. Recent meta-analysis and imaging studies do however indicate that there may be a significant clinical benefit in lowering the locoregional failures by using these compounds. Latest technological advancement in radiotherapy has allowed to deliver high doses of radiation conformally to the tumor volume. Although this technology has brought superb clinical responses for many types of cancer, recent modeling studies have predicted that tumor hypoxia is even more serious because 'reoxygenation' is low thereby leaving a large portion of hypoxic tumor cells behind. Wouldn't it be then reasonable to combine hypoxic radiosensitizers and/or hypoxia-selective cytotoxin with the latest radiotherapy? We will provide some preclinical and clinical evidence to support this idea hoping to revamp an enthusiasm for hypoxic radiosensitizers or hypoxia-selective cytotoxins as an adjunct therapy for radiotherapy.

#Hypoxia #Radiosensitizers #Hypoxia-selective cytotoxin #Reoxygenation #Hyperfractionation #Hypofractionation

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!